Compare Incyte Corporation (INCY) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Warner Music Group Corp — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Warner Music Group Corp trades at $28.76 (market cap $15.12B). The key difference: Incyte Corporation is the larger of the two by market cap, and Warner Music Group Corp pays a 2.77% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Warner Music Group Corp for 96 Days on average.
| INCY | WMG | |
|---|---|---|
Market Cap | $22.85B | $15.12B |
Volume | 1,927,029 | 2,966,414 |
Sector | Health | Media |
52-Week High | $129.93 | $34.72 |
52-Week Low | $83.80 | $23.65 |
Typical Hold Time | 33 Days | 96 Days |
Enterprise Value | $18.35B | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Warner Music Group (WMG) trades at $28.72, up 1.99% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and maintains a robust gross profit margin of 45.77%. Recent news highlights strategic AI partnerships and licensing renewals, signaling growth initiatives. Revenue has grown from $5.9B in 2022 to $6.7B in 2025, with a projected increase to $7.3B in 2026.
The outlook for WMG is positive, driven by earnings beats, analyst optimism, and AI-driven content curation opportunities. Key risks include competitive pressures in the music industry and execution challenges amid leadership changes. The consensus price target of $39.50 implies significant upside, but investors should monitor margin trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
